Show simple item record

dc.contributor.authorFoster, GR
dc.contributor.authorChayama, K
dc.contributor.authorChuang, W-L
dc.contributor.authorFainboim, H
dc.contributor.authorFarkkila, M
dc.contributor.authorGadano, A
dc.contributor.authorGaeta, GB
dc.contributor.authorHezode, C
dc.contributor.authorInada, Y
dc.contributor.authorHeo, J
dc.contributor.authorKumada, H
dc.contributor.authorLu, S-N
dc.contributor.authorMarcellin, P
dc.contributor.authorMoreno, C
dc.contributor.authorRoberts, SK
dc.contributor.authorStrasser, SI
dc.contributor.authorThompson, AJ
dc.contributor.authorToyota, J
dc.contributor.authorPaik, SW
dc.contributor.authorVierling, JM
dc.contributor.authorZignego, AL
dc.contributor.authorCohen, D
dc.contributor.authorMcPhee, F
dc.contributor.authorWind-Rotolo, M
dc.contributor.authorSrinivasan, S
dc.contributor.authorHruska, M
dc.contributor.authorMyler, H
dc.contributor.authorPortsmouth, SD
dc.date.accessioned2020-12-21T01:14:40Z
dc.date.available2020-12-21T01:14:40Z
dc.date.issued2016-08-19
dc.identifierpii: 2920
dc.identifier.citationFoster, G. R., Chayama, K., Chuang, W. -L., Fainboim, H., Farkkila, M., Gadano, A., Gaeta, G. B., Hezode, C., Inada, Y., Heo, J., Kumada, H., Lu, S. -N., Marcellin, P., Moreno, C., Roberts, S. K., Strasser, S. I., Thompson, A. J., Toyota, J., Paik, S. W. ,... Portsmouth, S. D. (2016). A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3. SPRINGERPLUS, 5 (1), https://doi.org/10.1186/s40064-016-2920-z.
dc.identifier.issn2193-1801
dc.identifier.urihttp://hdl.handle.net/11343/256429
dc.description.abstractBACKGROUND AND PURPOSE: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. METHODS: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). RESULTS: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. CONCLUSION: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV.
dc.languageEnglish
dc.publisherSPRINGER INTERNATIONAL PUBLISHING AG
dc.titleA randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3
dc.typeJournal Article
dc.identifier.doi10.1186/s40064-016-2920-z
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titleSpringerPlus
melbourne.source.volume5
melbourne.source.issue1
dc.rights.licenseCC BY
melbourne.elementsid1094569
melbourne.contributor.authorThompson, Alexander
dc.identifier.eissn2193-1801
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record